|1.||Muñoz, Miguel: 28 articles (01/2015 - 06/2004)|
|2.||Coveñas, Rafael: 22 articles (01/2015 - 07/2005)|
|3.||Rosso, Marisa: 14 articles (01/2014 - 06/2004)|
|4.||Bhatia, Madhav: 14 articles (07/2012 - 02/2005)|
|5.||Pothoulakis, Charalabos: 13 articles (01/2014 - 12/2002)|
|6.||Navari, Rudolph M: 10 articles (09/2015 - 06/2002)|
|7.||Douglas, Steven D: 10 articles (05/2015 - 12/2004)|
|8.||Mantyh, Patrick W: 8 articles (04/2015 - 01/2002)|
|9.||Leeman, Susan E: 8 articles (10/2011 - 07/2003)|
|10.||Bunnett, Nigel W: 7 articles (08/2015 - 06/2004)|
01/01/2004 - "This knowledge is now being fruitfully used in the development of non-peptide NK(1) receptor antagonists that essentially block the pharmacological effects of SP. It is now being realized that the simultaneous blockade of two or more receptors gives promising results in emesis, depression and pulmonary obstructive diseases. "
07/01/2000 - "The data of NK-1 receptor antagonists in the control of acute emesis, although promising, need confirmation in a properly designed study."
01/05/2014 - "Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis."
01/01/2004 - "The NK-1 receptor antagonists have activity in controlling emesis induced by peripherally acting and centrally acting emetogens, suggesting a mechanism of action at multiple sites. "
01/01/2002 - "4. Central NK(1) receptors are involved in PDE4 inhibitor-induced emesis. "
12/01/2011 - "Neurokinin-1 receptor antagonists are effective in reducing the incidence of vomiting, but not nausea. "
01/01/2014 - "In clinical trials there is a singular success: neurokinin 1 receptor antagonists to treat nausea and vomiting. "
04/01/2008 - "Cannabinoid and neurokinin-1 receptor antagonists are best reserved for refractory cases of nausea and vomiting. "
04/30/2006 - "Identification of treatments for nausea and vomiting and reduction of emetic liability of new therapies has largely relied on the use of animal models, and although such models have proven invaluable in identification of the anti-emetic effects of both 5-hydroxytryptamine(3) and neurokinin(1) receptor antagonists selection of appropriate models is still a matter of debate. "
07/01/2008 - "Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities."
|3.||Postoperative Nausea and Vomiting (PONV)
04/01/2011 - "Neurokinin-1 (NK(1)) receptor antagonists have been shown to be safe and effective for the prevention and treatment of PONV in humans. "
05/01/2015 - "Newly developed neurokinin-1 receptor (NK-1R) antagonists have been recently tried in the prevention of postoperative nausea and vomiting (PONV). "
05/01/2015 - "Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis."
07/01/2009 - "Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting."
08/01/2008 - "To review the characteristics of neurokinin-1 receptor antagonists and their potential role in the management of postoperative nausea and vomiting. "
01/01/2014 - "This study has examined the ability of the ChemR23 agonist, chemerin, to modulate synaptic input to lamina I neurokinin 1 receptor expressing (NK1R+) dorsal horn neurons, which are known to be crucial for the manifestation of inflammatory pain. "
01/01/2014 - "The chemerin receptor 23 agonist, chemerin, attenuates monosynaptic C-fibre input to lamina I neurokinin 1 receptor expressing rat spinal cord neurons in inflammatory pain."
10/01/2013 - "Blockade of substance P receptor attenuates osteoporotic pain, but not bone loss, in ovariectomized mice."
07/01/2013 - "Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain."
09/01/2012 - "Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain."
04/01/2005 - "5. In conclusion, the present study has used novel techniques in WT and NK(1) knockout mice to show that SP can modulate vascular tone and permeability in the inflamed joint via activation of the NK(1) receptor and that SP-induced responses are more pronounced where pre-existing inflammation is present."
08/15/2015 - "Inflammation-induced abnormalities in the subcellular localization and trafficking of the neurokinin 1 receptor in the enteric nervous system."
11/08/2012 - "Changes in response properties of rostral ventromedial medulla neurons during prolonged inflammation: modulation by neurokinin-1 receptors."
06/01/2012 - "Suppression of neurokinin-1 receptor in trigeminal ganglia attenuates central sensitization following inflammation."
02/09/2011 - "(5) pAkt and pmTOR are expressed in neurokinin 1 receptor-positive neurons in laminae I-III after peripheral inflammation. "
|3.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|5.||Serotonin (5 Hydroxytryptamine)
|6.||Neurokinin-2 Receptors (Neurokinin 2 Receptor)
|1.||Drug Therapy (Chemotherapy)